Affiliation:
1. Laboratorio de Higiene, Inspección y Control de Alimentos, Departamento de Química Analítica, Nutrición y Bromatología, Campus Terra, Universidade da Santiago de Compostela, 27002 Lugo, Spain
Abstract
Different research studies have identified specific groups or certain dietary compounds as the onset and progression of obesity and suggested that gut microbiota is a mediator between these compounds and the inflammation associated with pathology. In this study, the objective was to evaluate the dietary intake of 108 overweight (OW), obese (OB), and normal-weight (NW) individuals and to analyze their gut microbiota profile to determine changes and associations with Body Mass Index (BMI) and diet. When individuals were compared by BMI, significant differences in fiber and monounsaturated fatty acids (MUFAs) intake were observed, showing higher adequacy for the NW group. The analysis of gut microbiota showed statistical differences for 18 ASVs; Anaerostipes and Faecalibacterium decreased in the OW/OB group, whereas the genus Oscillospira increased; the genus was also found in the LEFSe analysis as a biomarker for OW/OB. Roseburia faecis was found in a significantly higher proportion of NW individuals and identified as a biomarker for the NW group. Correlation analysis showed that adequation to nutritional recommendation for fiber indicated a higher abundance of Prevotella copri, linearly correlated with F. prausnitzii, Bacteroides caccae, and R. faecis. The same correlation was found for the adequation for MUFAs, with these bacteria being more abundant when the intake was adjusted to or below the recommendations.
Funder
Ministry of Economy and Competitiveness
Subject
Food Science,Nutrition and Dietetics
Reference75 articles.
1. World Health Organization (WHO) (2021). Obesity and Overweight, World Health Organization. Available online: https://www.who.int/es/news-room/fact-sheets/detail/obesity-and-overweight.
2. Regulation of food intake, energy balance, and body fat mass: Implications for the pathogenesis and treatment of obesity;Guyenet;J. Clin. Endocrinol. Metab.,2012
3. Recent developments on the role of epigenetics in obesity and metabolic disease;Tellam;Clin. Epigenetics,2015
4. Instituto Nacional de Estadística (INE) (2022, October 31). Encuesta Europea de Salud en España (EESE) 2020. Ministerio de Sanidad. Available online: https://www.mscbs.gob.es/estadEstudios/estadisticas/EncuestaEuropea/EncuestaEuropea2020/EESE2020_inf_evol_princip_result.pdf.
5. Prevalencia de obesidad y factores de riesgo cardiovascular asociados en la población general española: Estudio ENPE;Rev. Esp. Cardiol.,2021